Sugi Predict

Sugi Predict / Compounds / SCHEMBL29453442

SCHEMBL29453442

SCHEMBL29453442

CCC1C(=O)N(C)c2cnc(Nc3ccc(C(=O)O)cc3OC)nc2N1C1CCCC1

nearest known ligand 0.87

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PLK1 P53350 18/20 0.87
▸ PLK3 Q9H4B4 14/20 0.87
▸ PLK2 Q9NYY3 13/20 0.87
▸ PRKD3 O94806 3/20 0.85
▸ CLK2 P49760 3/20 0.85
▸ PTK2 Q05397 3/20 0.85
▸ CAMK2G Q13555 3/20 0.85
▸ CAMK2D Q13557 3/20 0.85
▸ PRKD2 Q9BZL6 3/20 0.85
▸ CSNK1G1 Q9HCP0 3/20 0.85
▸ CSNK1G3 Q9Y6M4 3/20 0.85
▸ MAP4K4 O95819 2/20 0.85
▸ PRKCG P05129 2/20 0.85
▸ RPS6KA3 P51812 2/20 0.85
▸ NEK4 P51957 2/20 0.85
▸ SRPK1 Q96SB4 1/20 0.85
▸ BRD4 O60885 6/20 0.81
▸ ALK Q9UM73 5/20 0.81
▸ BRDT Q58F21 2/20 0.81
▸ DAPK3 O43293 2/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16971992 1.00 PLK1 (0.87) PLK1PLK3PLK2PRKD3CLK2
SCHEMBL29922386 1.00 PLK1 (0.87) PLK1PLK3PLK2PRKD3CLK2
SCHEMBL376134 1.00 PLK1 (0.87) PLK1PLK3PLK2PRKD3CLK2
SCHEMBL15257514 0.99 PLK1 (0.87) PLK1PLK3PLK2PRKD3CLK2
SCHEMBL30356851 0.94 PLK1 (0.81) PLK1PLK3PLK2PRKD3CLK2
SCHEMBL31098099 0.94 PLK1 (0.81) PLK1PLK3PLK2PRKD3CLK2
SCHEMBL12825254 0.94 PLK1 (0.84) PLK1PLK3PLK2PRKD3CLK2
SCHEMBL12323284 0.94 PLK1 (0.85) PLK1PLK3PLK2PRKD3CLK2
SCHEMBL14215917 0.93 PLK1 (0.80) PLK1PLK3PLK2PRKD3CLK2
SCHEMBL30325075 0.93 PLK1 (0.86) PLK1PLK3PLK2PRKD3CLK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250032623-A1 HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE HALDA THERAPEUTICS OPCO, INC. 2025-01-30 — — US disclosed
US-20240384007-A1 COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION NOVARTIS AG (CH) 2024-11-21 — — US disclosed
US-12023385-B2 Tunable endogenous protein degradation with heterobifunctional compounds DANA-FARBER CANCER INSTITUTE, INC. (US) 2024-07-02 — — US disclosed
US-11999802-B2 Compositions and methods for selective protein degradation NOVARTIS AG (CH) 2024-06-04 — — US disclosed
WO-2024054954-A1 HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE HALDA THERAPEUTICS OPCO, INC. (US) 2024-03-14 — — WO disclosed
WO-2023059583-A1 HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE HALDA THERAPEUTICS OPCO, INC. (US) 2023-04-13 — — WO disclosed
WO-2023059581-A1 HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE HALDA THERAPEUTICS OPCO, INC. (US) 2023-04-13 — — WO disclosed
EP-4119552-A1 REGULATING CHIMERIC ANTIGEN RECEPTORS Dana-Farber Cancer Institute, Inc. (US) 2023-01-18 — — EP disclosed
CN-108350062-B Targeted protein degradation to attenuate adverse inflammatory responses associated with adoptive T cell therapy 达纳-法伯癌症研究所股份有限公司 2022-10-14 — — CN disclosed
EP-3331905-B1 TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES DANA FARBER CANCER INST INC (US) 2022-10-05 — — EP disclosed
US-20220251152-A1 COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION NOVARTIS AG (CH) 2022-08-11 — — US disclosed
US-20220135967-A1 TUNABLE ENDOGENOUS PROTEIN DEGRADATION DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-05-05 — — US disclosed
US-11311609-B2 Regulating chimeric antigen receptors DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-04-26 — — US disclosed
US-11293023-B2 Tunable endogenous protein degradation DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-04-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12023385-B2 Tunable endogenous protein degradation with heterobifunctional compounds DBN1, MYCBP, PSMG3 PLK1 3075/4885PLK3 4761/4885PLK2 4750/4885
US-20240384007-A1 COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION CRBN, RPS27A, COPB1 PLK1 3433/4885PLK3 3123/4885PLK2 3177/4885
US-11293023-B2 Tunable endogenous protein degradation PSMG3, MYCBP, DBN1 PLK1 2709/4885PLK3 4748/4885PLK2 4713/4885
US-11311609-B2 Regulating chimeric antigen receptors NFATC1, TNFRSF9, IL2RA PLK1 1768/4885PLK3 4001/4885PLK2 3994/4885
US-11999802-B2 Compositions and methods for selective protein degradation CRBN, RPS27A, COPB1 PLK1 3433/4885PLK3 3123/4885PLK2 3177/4885
US-20250032623-A1 HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE AURKB, CDK9, AURKA PLK1 9/4885PLK3 519/4885PLK2 123/4885
US-20220251152-A1 COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION RPS27A, PSMG3, PREP PLK1 2361/4885PLK3 3345/4885PLK2 3402/4885
US-20220135967-A1 TUNABLE ENDOGENOUS PROTEIN DEGRADATION PSMG3, MYCBP, DBN1 PLK1 2709/4885PLK3 4748/4885PLK2 4713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.